TY - JOUR
T1 - Valproate attenuates dextroamphetamine-induced subjective changes more than lithium
AU - Willson, Morgan C.
AU - Bell, Emily C.
AU - Dave, Sanjay
AU - Asghar, Sheila J.
AU - McGrath, Brent M.
AU - Silverstone, Peter H.
N1 - Funding Information:
This work was supported in part by peer-reviewed grants from the Canadian Institutes of Health Research (CIHR) and the Alberta Heritage Foundation for Medical Research (AHFMR).
PY - 2005/12
Y1 - 2005/12
N2 - Dextroamphetamine administration in healthy controls produces a range of subjective and physiological effects, which have been likened to those occurring during mania. However, it is uncertain if these can be attenuated by lithium since conflicting results have been reported. To date there have been no previous studies examining the effects of valproate on dextroamphetamine-induced mood and physiological changes. The current study was a double-blind, placebo-controlled, study in which volunteers received either 1000 mg sodium valproate (n = 12), 900 mg lithium (n = 9), or placebo (n = 12) pre-treatment for 14 days. Subjective and physiological measures were then obtained prior to administration of a 25 mg dose of dextroamphetamine, and at two time points after administration. Differences in the response to dextroamphetamine were assessed between the three treatment groups. The results of this study show that pre-treatment with lithium only significantly attenuated dextroamphetamine- induced change in happiness, while valproate pre-treatment significantly attenuated the effects of dextroamphetamine on happiness, energy, alertness and on the diastolic blood pressure. These results suggest that lithium and valproate do not have the same mechanism of action on dextroamphetamine-induced changes, and this finding may relate to differences in their mechanism of action in mood disorders.
AB - Dextroamphetamine administration in healthy controls produces a range of subjective and physiological effects, which have been likened to those occurring during mania. However, it is uncertain if these can be attenuated by lithium since conflicting results have been reported. To date there have been no previous studies examining the effects of valproate on dextroamphetamine-induced mood and physiological changes. The current study was a double-blind, placebo-controlled, study in which volunteers received either 1000 mg sodium valproate (n = 12), 900 mg lithium (n = 9), or placebo (n = 12) pre-treatment for 14 days. Subjective and physiological measures were then obtained prior to administration of a 25 mg dose of dextroamphetamine, and at two time points after administration. Differences in the response to dextroamphetamine were assessed between the three treatment groups. The results of this study show that pre-treatment with lithium only significantly attenuated dextroamphetamine- induced change in happiness, while valproate pre-treatment significantly attenuated the effects of dextroamphetamine on happiness, energy, alertness and on the diastolic blood pressure. These results suggest that lithium and valproate do not have the same mechanism of action on dextroamphetamine-induced changes, and this finding may relate to differences in their mechanism of action in mood disorders.
UR - http://www.scopus.com/inward/record.url?scp=27744521375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744521375&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2005.04.015
DO - 10.1016/j.euroneuro.2005.04.015
M3 - Article
C2 - 15949922
AN - SCOPUS:27744521375
SN - 0924-977X
VL - 15
SP - 633
EP - 639
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 6
ER -